Connect Biopharma Holdings (CNTB) EBITDA Margin (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported EBITDA Margin for 3 consecutive years, with 11601.78% the latest figure, recorded in Q1 2026.

• Quarterly EBITDA Margin changed N/A year-over-year to 11601.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28426.61% (changed N/A YoY) and the FY2025 annual result came in at 90740.62%, down 9065438.0% from the prior year.
• EBITDA Margin improved to 11601.78% in Q1 2026 per CNTB's latest filing, from 110481.25% in the prior quarter.
• Over the last five years, EBITDA Margin for CNTB reached as high as 1135.85% in Q3 2024 and fell as low as 110481.25% in Q3 2025.
• A 3-year average of 30512.72% and a median of 11601.78% in 2026 frame the typical range for EBITDA Margin.
• The largest YoY upside for EBITDA Margin was 10934540 bps in 2025 against a maximum downside of 10934540 bps in 2025.
• Year by year, EBITDA Margin stood at 1378.08% in 2024, then plunged by 7917 bps to 110481.25% in 2025, then surged by 89 bps to 11601.78% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 11601.78%, 110481.25%, and 27966.67% for Q1 2026, Q3 2025, and Q2 2025 respectively.